ProShare Advisors’s Structure Therapeutics GPCR Stock Holding History

ProShare Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,957	Closed	-$206K	–	1942
2025 Q4	$206K	Buy	+2,957	New	+$121K	﹤0.01%	1699

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ProShare Advisors's GPCR Position: Q1 2026 in Review

ProShare Advisors sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 2,957 shares — an estimated $206K sold.

ProShare Advisors first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $206K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

ProShare Advisors reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 2,957 Structure Therapeutics shares in Q1 2026, an estimated $206K.
ProShare Advisors first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
ProShare Advisors's Structure Therapeutics position peaked at $206K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.